Oligomenorrhea with different degrees of follicular and adrenal hyperandrogenism are the hallmarks of the condition of polycystic ovary syndrome (PCOS). For some of the women in their reproductive years, this endocrine illness is incredibly prevalent and comprises a variety of disorders. There are a set of symptoms, such as hirsutism, acne, and insulin resistance, for identifying the characteristics of PCOS. Various treatment modalities have been opted for over the years for the treatment and management of this condition, among which metformin and flutamide are the most prevalent, along with lifestyle modifications as prevalent recommendations to patients. Weight management for obese patients is the most challenging aspect of PCOS management. Still, similar findings are found in women with lean physiology or a normal BMI, indicating that PCOS symptoms prevail and occur irrespective of the BMI, but obese or overweight women face more problems. We determined the long-term effects of treatment modalities on PCOS symptoms and their improvement. Metformin was reported to primarily increase the blood levels of glucose as well as BMI. Blood pressure was also maintained among various researchers, and DHEAS levels were also altered along with serum sex hormone-binding globulin in the plasma of patients undergoing treatments specific for PCOS patients with a normal BMI or lean PCOS. Further studies with more extensive parameters being employed need to be conducted for the determination of the exact mechanism and cause of the disease to ease the treatment process.
Aim: The aim of this systematic review is to comprehensively assess and analyze the impact of proton pump inhibitors on kidney function and their potential role in the progression of chronic kidney disease. Through a meticulous examination of available literature, we aim to provide a clear understanding of the relationship between proton pump inhibitor use and kidney health, shedding light on potential risks, benefits, and contributing factors. Ultimately, this research aims to inform healthcare professionals and patients alike about the implications of proton pump inhibitors on kidney function, facilitate informed medical decisions, and improve patient care. Methods: We used the following medical subject headings (MeSH) terms with keywords like "irritable bowel syndrome" and "kidney injury" to gather data from the National Library of Medicine (PubMed), PubMed Central (PMC), and Google Scholar. Articles from the last 10 years, 2013 to 2023, were gathered for this systematic review. Results: The results indicate a complex relationship between proton pump inhibitors and kidney function, as well as the progression of chronic kidney disease. Conclusion: In the end, this systematic review shows that there is a link between long-term use of proton pump inhibitors and a higher risk of kidney problems. Patients and healthcare providers should weigh the benefits of proton pump inhibitor therapy against potential risks, especially in individuals with pre-existing kidney conditions, and consider alternative treatment options when appropriate. Regular monitoring of kidney function in proton pump inhibitor users may also be advisable to ensure early detection and management of any adverse effects.
An eight‐year‐old girl presented with a first episode of focal seizure and transient loss of consciousness. Brain MRI revealed a large subacute infarct in the left fronto‐parieto‐temporal region, and MR angiography showed bilateral supraclinoid internal carotid and proximal posterior cerebral artery narrowing with extensive basal collateral formation, consistent with Moyamoya disease. The absence of aneurysm or arteriovenous malformation excluded other vascular anomalies. She was managed with hypertonic saline, intravenous antibiotics, and antiplatelet therapy, followed by stabilization and referral for surgical revascularization. This case underscores the importance of maintaining a high index of suspicion for Moyamoya disease in children presenting with new‐onset seizures or stroke‐like episodes. Early neuroimaging and multidisciplinary management are essential to prevent further ischemic injury and optimize neurological outcomes.
Systemic lupus erythematosus (SLE) is an intricate autoimmune disorder that can manifest a plethora of symptoms. Tissue-binding autoantibodies and intricate immune complexes orchestrate the initial harm to organs and cellular structures. Amid its expansive array of manifestations, dermatological indications, notably digital gangrene and ulcers, are rare occurrences in the context of systemic lupus erythematosus and typically emerge in the advanced stages of the ailment. In this discussion, we present an exceptional case of early-onset digital gangrene and ulcers in a youthful patient grappling with systemic lupus erythematosus. This is a case study of a 7-year-old male who sought medical attention with urticarial rashes over his entire body and face, skin desquamation, and sporadic fever episodes. The preliminary assessment encountered challenges in distinguishing this presentation from acute urticaria. However, subsequent in-depth diagnostic scrutiny and serological analysis substantiated the patient's affliction with SLE. Digital gangrene, ulcers, and vasculitis became evident at the distal portions of the fingers. The diagnosis was conclusively established through clinical and serological methods. The patient exhibited positive results for antinuclear antibodies (ANA), anti-ribonuclear protein (Anti-RNP) antibodies, anti-Smith (Anti-Sm) antibodies, and anti-Sjögren's syndrome-related antigen A (Anti-SS-A) antibodies. This case underscores the pivotal importance of acknowledgment of the rare and severe manifestations of SLE in the realm of medical practice.
Purpose The complicated condition known as type 2 diabetes mellitus (T2DM) has a diverse genetic and environment-related cause. MIM125853 is among the heterogeneous diseases that can also be characterized as a multifactorial disorder of glucose metabolism with genetic susceptibility of an anomaly in the insulin pathway. We conducted the review with aim to assess the genetic variants affecting the insulin pathway as well as evaluate the risk of diabetes in association with genetic variants. Methods We used literature of 13 researches that met the inclusion criteria after the process of selection and analyzation. Our analysis included 59,593 participants in total with a gender distribution of 48% males (n = 24,591) and 52% females (n = 35,002). Result Gene variants such as PPARG, SLC30A8, KCNJ11, TCF7L2 and many others plays a pivotal role in the development of type-II diabetes as well as optimal functioning of insulin metabolic pathway for glucose metabolism and distribution with circulation. Conclusion KCNJ11 regulates insulin release in collaboration with other genes including ABCC8, KAPN10, IRS1 and TCF7L2. Reduced mutual expression of these kinds of genes could contribute to DM susceptibility. However, it is still unknown how precisely the combination of these genes’ functions in the control of insulin secretion.